CN Patent

CN121159702B — 一种重组质粒纳米抗体突变体m1及其制备方法与应用

Assigned to Guangdong University of Technology · Expires 2026-03-20 · 0y expired

What this patent protects

本发明公开了一种重组质粒纳米抗体突变体M1及其制备方法与应用，旨在提供一种重组质粒纳米抗体突变体M1，该重组质粒纳米抗体突变体M1与抗原的亲和力强，检测HCC时灵敏度高，特异性强；所述的重组质粒纳米抗体突变体M1的氨基酸序列如SEQ ID NO.2所示；属于生物技术领域。

USPTO Abstract

本发明公开了一种重组质粒纳米抗体突变体M1及其制备方法与应用，旨在提供一种重组质粒纳米抗体突变体M1，该重组质粒纳米抗体突变体M1与抗原的亲和力强，检测HCC时灵敏度高，特异性强；所述的重组质粒纳米抗体突变体M1的氨基酸序列如SEQ ID NO.2所示；属于生物技术领域。

Drugs covered by this patent

olezarsen-sodium (OLEZARSEN SODIUM)

Patent Metadata

Patent number: CN121159702B
Jurisdiction: CN
Classification: —
Expires: 2026-03-20
Drug substance claim: No
Drug product claim: No
Assignee: Guangdong University of Technology
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.